DIA Deliverables – Dispatches from the Drug Industry Association 2015 Annual Meeting
This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below.
Once in a blue moon, as the saying goes, the Drug Industry Association and Biotechnology Industry Organization convene their annual conclaves during the same week. So I spent the first part of the week at the DIA meeting in Washington DC before joining BIO2015 in progress here in Philadelphia and am sharing initial reflections on interesting developments from both.
My first thoughts on the 51st DIA Annual Meeting relate to some interesting take-aways from the DIA Convention Floor. It was very interesting for me to see meaningful indicators of the increasingly important role of women in strategic planning and business development for DIA Exhibitors as evidenced by branding, marketing and promotional incentives.
Tim Hunt debacle, of course, and so more likely to notice the trend. I would be interested in feedback from others who may have visited DIA this year.
I would also like to give a shout-out to BioMedical Systems, a Clinical Trial Services organization which celebrated its 40th birthday complete with cupcakes and champagne on the DIA Convention Floor. BioMedical Systems initiated clinical trial diagnostic services in 1975 and over the years has expanded to provide a wide-range of clinical trial support services. In an age where CROs seem to spring up like new grass after the rain, it was interesting for me to learn about a company with deep roots in St. Louis and growing global presence in Europe and Asia.
About the author:
President of Finston Consulting LLC since 2005, Susan works with innovative biotechnology and other clients ranging from start-up to Fortune-100, providing support for legal, transactional, policy and “doing business” issues in the US and globally. Together with biotechnology pioneer Ananda Chakrabarty, she also is co-founder of Amrita Therapeutics Ltd., an emerging biopharmaceutical company based in India with peptide drugs in in vivo research. Previous experience includes 11 years in the U.S Foreign Service with overseas tours in London, Tel Aviv, and Manila and at the Department of State in Washington DC. For more information on latest presentations and publications please visit finstonconsulting.com.
Comments are closed.